top of page
ABOUT US
​​
-
One of the longest, established, privately held biotech companies, founded in 1978.
​
-
Leading global provider of high-quality raw materials to the in-vitro diagnostic industry and research laboratories.
​
-
ISO 13485:2016 registered.
-
Joined the Biosynth Group to form the biologics division in May 2022.
-
Rebranded to Biosynth Ltd. on 1st August 2023.
KEY CAPABILITIES
​​
-
First to market proteins and monoclonal antibodies for the new emerging viruses, eg. Dengue, Chikungunya and Zika, Sars, Covid -19 and VEEV virus.
​
-
Wide range of well-established products for chemiluminscence, ELISA, lateral flow and other immunoassay formats.
-
Custom manufacture of antibodies and recombinant antigens under ISO 13485:2016 conditions
OUR GOAL
​​
-
To maintain our position as the leading global provider of high-quality and esoteric biological raw materials to the in-vitro diagnostic industry.
​
-
To enable our customers to bring ground-breaking technology to the market faster allowing cost-effective and efficient patient management at the point of impact.
bottom of page